Classic Hodgkin lymphoma
- 1 December 2023
- journal article
- review article
- Published by Wiley in Hematological Oncology
- Vol. 42 (6)
Abstract
Classic Hodgkin lymphoma (HL) is rare disease, with an incidence of approximately 85,000 patients globally per year and a predilection for adolescents and young adults (ages 15–39). Since the introduction of combination chemotherapy in the 1960's and radiation dating back to the early 1900's, therapeutic options and by extension, clinical outcomes have improved dramatically with 5‐year overall survival (OS) approaching 90% today. [1](#ref‐0001) Advances in understanding HL biology have additionally facilitated development of targeted agents and immunotherapy which have further improved short and long‐term outcomes. Despite continued improvements in up‐front and salvage therapy, long‐term survivors of HL experience several treatment‐associated late toxicities, thus, along with efforts to improve therapeutic efficacy, efforts to reduce late effects remain a high‐priority in the field.Keywords
This publication has 31 references indexed in Scilit:
- Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 TrialJournal of Clinical Oncology, 2017
- Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s LymphomaNew England Journal of Medicine, 2016
- Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology GroupInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s LymphomaNew England Journal of Medicine, 2015
- Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: Benefit of deep inspiration breath-holdActa Oncologica, 2014
- Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology GroupInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell deathOncoImmunology, 2014
- Radiation for Hodgkin's Lymphoma in Young Female Patients: A New Technique to Avoid the Breasts and Decrease the Dose to the HeartInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's DiseaseNew England Journal of Medicine, 2007